Clinical Trials
453
Active:11
Completed:73
Trial Phases
6 Phases
Early Phase 1:11
Phase 1:25
Phase 2:103
+3 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (340 trials with phase data)• Click on a phase to view related trials
Not Applicable
154 (45.3%)Phase 2
103 (30.3%)Phase 4
28 (8.2%)Phase 1
25 (7.4%)Phase 3
19 (5.6%)Early Phase 1
11 (3.2%)Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
Not Applicable
Recruiting
- Conditions
- Follicular LymphomaTreatment Naive
- Interventions
- Drug: zanubrutinib, bendamustine, and obinutuzumab
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Target Recruit Count
- 15
- Registration Number
- NCT07126678
- Locations
- 🇨🇳
Jiangsu Province Hospital, Nanjing, Jiangsu, China
Feasibility and Safety of Laparoscopic Purse-string Suture Clamp and Multi-functional Seal Cap for Totally Laparoscopic Radical Total Gastrectomy
Not Applicable
Not yet recruiting
- Conditions
- Gastric Cancer (GC)GastrectomyAnastomosis, Roux-en-YLaparoscopic
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-08-15
- Target Recruit Count
- 50
- Registration Number
- NCT07117812
QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
Not Applicable
Not yet recruiting
- Conditions
- Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
- Interventions
- Drug: QL1706 + olaparib
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Target Recruit Count
- 79
- Registration Number
- NCT07113964
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Prospective Study on Exemption of Tumor Bed Boost Radiotherapy for pCR Patients After Breast Conserving Surgery With Neoadjuvant Therapy
Not Applicable
Recruiting
- Conditions
- Breast Cancer
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Target Recruit Count
- 150
- Registration Number
- NCT07113613
- Locations
- 🇨🇳
The First Affiliated with Nanjing Medical University (Jiangsu Province People's Hospital), Nanjing, Jiangsu, China
Diagnostic Application of AI-ROSE in Severe Pneumonia
- Conditions
- Severe PneumoniaBacterial Infections
- First Posted Date
- 2025-08-11
- Last Posted Date
- 2025-08-11
- Target Recruit Count
- 100
- Registration Number
- NCT07113951
- Locations
- 🇨🇳
Fluorescence Biological Microscope, Nanjing, Jiangsu, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 91
- Next
News
No news found